Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To report about the outcome of radiation treatment of advanced lung cancer patients with volumetric modulated arcs [RapidArc (RA)].

Patients and methods: Seventy-five consecutive patients (all stages IIIA and IIIB) were treated with RA. Among them 71 % were men; 25.4 % presented unspecified non-small cell lung cancer, 41.3% adenocarcinoma and 33.3 % squamous cell carcinoma. Of them, 54.7 % received sequential chemotherapy while 45.3% were treated with concomitant regimen. Dose prescription ranged from 54 to 72 Gy. Analysis included survival, local control (LC) and toxicity profiles.

Results: Median follow-up was 21.2 months (range 6–75). One- two- and five-year actuarial LC was 91.9 ± 3.2, 79.5 ± 5.7 and 67.4 ± 9.5 %, respectively. Median survival was 19.0 ± 1.1 months. Actuarial survival at 1–2–5 years was 80.0 ± 4.6, 38.5 ± 5.9 and 15.2 ± 4.9 %, respectively. Acute toxicity of G2 was reported in 24, 25.3 and 4.0 % of patients for lung, esophageal and hematological profiles. A total of 2.7 % of patients reported G3 toxicity in the esophagus and 5.3 % of the patients experienced G3–G4 hematological toxicity. Significant differences were observed in all cases between concomitant and sequential chemotherapy regiments. Only 1.3 % (1 patient) showed G2 lung late toxicity. No significant correlation was found between toxicity and organ’s irradiation levels.

Conclusion: RA proved to be a safe and advantageous treatment modality for advanced lung cancer with results in line with expectations from earlier literature.

Original languageEnglish
Pages (from-to)1937-1945
Number of pages9
JournalJournal of Cancer Research and Clinical Oncology
Volume140
Issue number11
DOIs
Publication statusPublished - Oct 14 2014

Fingerprint

Intensity-Modulated Radiotherapy
Lung Neoplasms
Therapeutics
Drug Therapy
Lung
Survival
Survival Analysis
Non-Small Cell Lung Carcinoma
Esophagus
Prescriptions
Squamous Cell Carcinoma
Adenocarcinoma
Radiation

Keywords

  • Lung
  • RapidArc
  • VMAT

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

@article{21900244c705426aa44ecd372ad4d782,
title = "Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy",
abstract = "Purpose: To report about the outcome of radiation treatment of advanced lung cancer patients with volumetric modulated arcs [RapidArc (RA)].Patients and methods: Seventy-five consecutive patients (all stages IIIA and IIIB) were treated with RA. Among them 71 {\%} were men; 25.4 {\%} presented unspecified non-small cell lung cancer, 41.3{\%} adenocarcinoma and 33.3 {\%} squamous cell carcinoma. Of them, 54.7 {\%} received sequential chemotherapy while 45.3{\%} were treated with concomitant regimen. Dose prescription ranged from 54 to 72 Gy. Analysis included survival, local control (LC) and toxicity profiles.Results: Median follow-up was 21.2 months (range 6–75). One- two- and five-year actuarial LC was 91.9 ± 3.2, 79.5 ± 5.7 and 67.4 ± 9.5 {\%}, respectively. Median survival was 19.0 ± 1.1 months. Actuarial survival at 1–2–5 years was 80.0 ± 4.6, 38.5 ± 5.9 and 15.2 ± 4.9 {\%}, respectively. Acute toxicity of G2 was reported in 24, 25.3 and 4.0 {\%} of patients for lung, esophageal and hematological profiles. A total of 2.7 {\%} of patients reported G3 toxicity in the esophagus and 5.3 {\%} of the patients experienced G3–G4 hematological toxicity. Significant differences were observed in all cases between concomitant and sequential chemotherapy regiments. Only 1.3 {\%} (1 patient) showed G2 lung late toxicity. No significant correlation was found between toxicity and organ’s irradiation levels.Conclusion: RA proved to be a safe and advantageous treatment modality for advanced lung cancer with results in line with expectations from earlier literature.",
keywords = "Lung, RapidArc, VMAT",
author = "Marta Scorsetti and Piera Navarria and {De Rose}, Fiorenza and Ascolese, {AnnaMaria M.} and Elena Clerici and Ciro Franzese and Francesca Lobefalo and Giacomo Reggiori and Pietro Mancosu and Stefano Tomatis and Antonella Fogliata and Luca Cozzi",
year = "2014",
month = "10",
day = "14",
doi = "10.1007/s00432-014-1739-7",
language = "English",
volume = "140",
pages = "1937--1945",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy

AU - Scorsetti, Marta

AU - Navarria, Piera

AU - De Rose, Fiorenza

AU - Ascolese, AnnaMaria M.

AU - Clerici, Elena

AU - Franzese, Ciro

AU - Lobefalo, Francesca

AU - Reggiori, Giacomo

AU - Mancosu, Pietro

AU - Tomatis, Stefano

AU - Fogliata, Antonella

AU - Cozzi, Luca

PY - 2014/10/14

Y1 - 2014/10/14

N2 - Purpose: To report about the outcome of radiation treatment of advanced lung cancer patients with volumetric modulated arcs [RapidArc (RA)].Patients and methods: Seventy-five consecutive patients (all stages IIIA and IIIB) were treated with RA. Among them 71 % were men; 25.4 % presented unspecified non-small cell lung cancer, 41.3% adenocarcinoma and 33.3 % squamous cell carcinoma. Of them, 54.7 % received sequential chemotherapy while 45.3% were treated with concomitant regimen. Dose prescription ranged from 54 to 72 Gy. Analysis included survival, local control (LC) and toxicity profiles.Results: Median follow-up was 21.2 months (range 6–75). One- two- and five-year actuarial LC was 91.9 ± 3.2, 79.5 ± 5.7 and 67.4 ± 9.5 %, respectively. Median survival was 19.0 ± 1.1 months. Actuarial survival at 1–2–5 years was 80.0 ± 4.6, 38.5 ± 5.9 and 15.2 ± 4.9 %, respectively. Acute toxicity of G2 was reported in 24, 25.3 and 4.0 % of patients for lung, esophageal and hematological profiles. A total of 2.7 % of patients reported G3 toxicity in the esophagus and 5.3 % of the patients experienced G3–G4 hematological toxicity. Significant differences were observed in all cases between concomitant and sequential chemotherapy regiments. Only 1.3 % (1 patient) showed G2 lung late toxicity. No significant correlation was found between toxicity and organ’s irradiation levels.Conclusion: RA proved to be a safe and advantageous treatment modality for advanced lung cancer with results in line with expectations from earlier literature.

AB - Purpose: To report about the outcome of radiation treatment of advanced lung cancer patients with volumetric modulated arcs [RapidArc (RA)].Patients and methods: Seventy-five consecutive patients (all stages IIIA and IIIB) were treated with RA. Among them 71 % were men; 25.4 % presented unspecified non-small cell lung cancer, 41.3% adenocarcinoma and 33.3 % squamous cell carcinoma. Of them, 54.7 % received sequential chemotherapy while 45.3% were treated with concomitant regimen. Dose prescription ranged from 54 to 72 Gy. Analysis included survival, local control (LC) and toxicity profiles.Results: Median follow-up was 21.2 months (range 6–75). One- two- and five-year actuarial LC was 91.9 ± 3.2, 79.5 ± 5.7 and 67.4 ± 9.5 %, respectively. Median survival was 19.0 ± 1.1 months. Actuarial survival at 1–2–5 years was 80.0 ± 4.6, 38.5 ± 5.9 and 15.2 ± 4.9 %, respectively. Acute toxicity of G2 was reported in 24, 25.3 and 4.0 % of patients for lung, esophageal and hematological profiles. A total of 2.7 % of patients reported G3 toxicity in the esophagus and 5.3 % of the patients experienced G3–G4 hematological toxicity. Significant differences were observed in all cases between concomitant and sequential chemotherapy regiments. Only 1.3 % (1 patient) showed G2 lung late toxicity. No significant correlation was found between toxicity and organ’s irradiation levels.Conclusion: RA proved to be a safe and advantageous treatment modality for advanced lung cancer with results in line with expectations from earlier literature.

KW - Lung

KW - RapidArc

KW - VMAT

UR - http://www.scopus.com/inward/record.url?scp=84919486615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919486615&partnerID=8YFLogxK

U2 - 10.1007/s00432-014-1739-7

DO - 10.1007/s00432-014-1739-7

M3 - Article

C2 - 24934724

AN - SCOPUS:84919486615

VL - 140

SP - 1937

EP - 1945

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 11

ER -